By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


NICE positive about lung cancer drug

Draft guidance has recommended afatinib (Giotrif) as a treatment for locally advanced, or metastatic, non-small-cell lung cancer.

The National Institute for Health and Care Excellence proposed that it be given to patients whose tumours test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and have not previously received an EGFR-TK inhibitor.

Sir Andrew Dillon

Sir Andrew Dillon

The drug, which is made by Boehringer Ingelheim, works by blocking the signal pathways helping to slow the growth and spread of tumours.

Sir Andrew Dillon, chief executive of NICE, said: “We’ve already recommended two drugs, gefitinib and erlotinib, as options for the first-line treatment for patients with this form of lung cancer and we’re pleased that this draft guidance recommends a further option.”




Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!